1 2

Ultrabiotic

Ultrabiotic

$42.03 USD
$42.03 USD
Sale Sold out
View full details

Digestive, Immune, and Allergy Support

Ultrabiotic by Aceva is not your average probiotic. Boasting 50% more bacteria than advertised, it's designed to enrich your gut with premium, active strains for enhanced digestive health and immune support. While most brands only highlight the bacterial count, Ultrabiotic emphasizes the quality, age, and in-depth research of its strains to deliver optimal results.

Why You Need Probiotics.

Digestive health is a critical issue in the United States, affecting over 70 million people and leading to staggering medical costs of $100 billion annually. With 50 million medical visits each year attributed to digestive disorders, the need for effective solutions has never been greater. Discover how our innovative products can help you achieve optimal digestive health and join the movement towards a healthier future.

Antibiotics, while crucial for treating infections, can inadvertently harm our gut's bacterial balance. This disruption in our internal ecosystem might lead to chronic infections, nutrient deficiencies, and subpar digestion. It's startling, but regaining this bacterial harmony can take up to half a year after a single antibiotic course. This underlines the importance of premium probiotics post any antibiotic regimen.

Why Aceva's Ultrabiotic stands out:

  • Deep Research: We don't just choose any bacteria. Our strains are backed by 23 research studies, highlighting their potency across various health conditions.
  • Beyond Numbers: Many market their probiotics merely by their bacterial count. At Aceva, we delve deeper - focusing on the bacteria's quality, its age, and the scientific research supporting each strain.
  • Potency Guaranteed: Our capsules contain 50% more bacteria than what's on the label. But it's not just about the count - it's about efficacy.
  • Optimal Harvesting: We harvest and freeze-dry our bacteria during their peak activity stage. This ensures that when they reach your gut, they're lively, resilient, and ready to work.

Responsive Video

Suggested Use

As a dietary supplement, take one (1) capsule one time per day or as directed by your healthcare professional.


Formulated To Be Free of Allergens Derived From:

Wheat, soy, eggs, fish, crustacean shellfish, tree nuts, peanuts, artificial preservatives, sweeteners, color and flavors.


Caution: As with any dietary supplement, consult your healthcare professional before using this product, especially if you are pregnant, nursing, anticipate surgery, take any medication or are otherwise under medical supervision. 

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. 

Citations:

1. D. Zabolotny, L. Shynkarenko, O. Melnikov, L. Volosevich, І. Zarytska, О. Goloborodko, G. Karpenko, О. Bolyska, D. Zabolotna. Application of the probiotic medication “Acidolor” (L.rhamnosus LB3) in patients with chronic tonsillitis and evaluation of its efficacy; Journal of ear, nose and throat diseases, No5, 2003, page.2-9
2. D. Zabolotny, L. Volosevich, І. Zarytskа, V.D. Zabolotna. Perspectives of biotherapy in ENT diseases; Journal of ear, nose and throat diseases, No3-с, 2003, p.180-181
3. O. Volska, D. Zabolotna. Study of the mechanisms of antagonistic activity of the Probiotics drugs. Journal of ear, nose and throat diseases, No3-с, 2003, p.164-165
4. L. Shynkarenko, N. Dehtyrenko. Research of the Chemotherapy drugs influence on Lactic Acid Bacteria cells. Scientific news of the NTU “KPI”, 2004, 1 (33), pp.135-140
5. Shynkarenko L., Dehtyrenko N. Adhesion potency of lactic acid bacteria as factor for selection of Probiotic strains. Scientific news of the NTU “KPI”, 2004, 3 (35), pp.102-106
6. Zabolotny D., Melnilkov О., Zabolotnaya D., Shynkarenko L. Probiotic modulation of the immunogenesis in the experiment. Immunology and allergy, 1, 2006., p.19-21
7. О. Melnikov, D. Zabolotnaya. Experimental investigation of the Probiotic influence on the palate tonsils cells in patients with chronic tonsillitis in vitro. The journal of ear, nose and throat diseases, 2006, 3, pp.24-27.
8. Volska, L. Shynkarenko, I. Zarytska, D. Zabolotna. Study of the possibility of the using of the Lactobacilli for treatment and prevention of the Candida infections in ENT-organs. Odessa medical Journal, 2006, 4 (96), pp.32-36
9. О. Melnikov, D. Zabolotnaya, L. Kalinovskaya, V. Simonenko. Investigation of the functional and morphochemical characteristics of the cells and tissues under the conditions of the co-cultivation with L.rhamnosus LB3. The journal of ear, nose and throat diseases, 4, 2007, 170-172.
10. Timoshok N, Shynkarenko L, Starovoytova S, Spivak N. Investigation of interferon induction activity of new Probiotic composition and strains L.delbrueckii 86, L.rhamnosus LB3 to compare with Del-Immune V and Lactobacterin (L.plantarum); 2009, IIX Congress of Ukrainian Microbiological Society, Abstracts Book, p.264
11. Starovoytova S, Timoshok N, Gorchakov V, Spivak N. Immunomodulating abilities of Lactic Acid Bacteria.2009; Microbiol.J.,V71, 3, pp.41-47
12. Report on clinical use of the probiotic cells Lactobacillus delbrueckii LE and their lysate. A.S Prylutskyy, MD, PhD, Clinical Immunology and Allergy Department, Donetsk State Medical University, 1999
13. Savtova Z.D., Shpylevaya S.I., Tarutinov V.I., Rogatskaya V.P., NMeniok T.A., Nikolsky I.S., Mosienko V.S., Shynkarenko L.M., Chekhun V.F. Immune correction by an Immunomodulator from lactobacillus delbrueckii LE in a combined therapy of breast cancer at stages II and IV. Oncology 2000; 22:211-214
14. Shpylevaya S.I., Tarutinov V.I., Mosienko V.S., Rogatskaya V.P., Ponomarev I.O., Shynkarenko L.M., Chekhun V.F. Correction of leucopenia by a new probiotic immunomodulator Lactobacillus delbrueckii product in combined treatment of breast cancer. Oncology, 2000; 2 (1-2):83-86
15. D. Zabolotny, L. Shynkarenko, О. Melnikov, L. Volosevich, І. Zarytska, О. Goloborodko, G. Karpenko, О. Bolyska, D. Zabolotna. Application of the probiotic medication “Acidolor” in patients with chronic tonsillitis and evaluation of its efficacy; Journal of ear, nose and throat diseases, No5, 2003, page.2-9
16. L. Shynkarenko, N. Dehtyrenko. Research of the Chemotherapy drugs influence on Lactic Acid Bacteria cells. Scientific news of the NTU “KPI”, 2004, 1 (33), pp.135-140
17. Volska, L. Shynkarenko, I. Zarytska, D. Zabolotna. Study of the possibility of the using of the Lactobacilli for treatment and prevention of the Candida infections in ENT-organs. Odessa medical Journal, 2006, 4 (96), pp.32-3
18. Starovoytova S., Gorchakov V. Lactic Acid Bacteria strain Selection for Effective Probiotics Compositions. 2006, Scientific News of NTU “KPI”, v5, pp.100-103
19. Starovoytova S, Timoshok N, Gorchakov V, Spivak N. Interferon induction activity of Lactic Acid Bacteria; 2007, Immunology and Allergy (Ukrainian), #4, pp. 24-27
20. Starovoytova S., Oryabinska L, Gorchakov V. Cholinesterase and protease activity of Lactic Acid Bacteria in vitro ; 2007, Environment and Health, #4 (43), pp.68-71
21. Starovoytova S, Timoshok N, Spivak N. Influence of Lactic Acid bacteria associated cultures at mice experimental meningoencephalytic herpes infection; 2008, In Abstracts of International Conference “Antibacterial and anti-viral therapy on hospital treatment”, Charkov, Ukraine, pp.316-317
22. Timoshok N, Shynkarenko L, Starovoytova S, Spivak N. Investigation of interferon induction activity of new Probiotic composition and strains L.delbrueckii 86, L.rhamnosus to compare with Del-Immune V and Lactobacterin (L.plantarum); 2009, IIX Congress of Ukrainian Microbiological Society, Abstracts Book, p.264
23. Starovoytova S, Timoshok N, Gorchakov V, Spivak N. Immunomodulating abilities of Lactic Acid Bacteria.2009; Microbiol.J., V71, #3, pp.41-47